Imalumab
Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth.[1][2] Phase I studies were completed in early 2016,[3] and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer.[2] It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.[4]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | BAX69 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
A phase I/II trial in patients with malignant ascites was terminated in 2016.[4]
References
- Douillard, Patrice; Thiele, Michael; Schinagl, Alexander; Halama, Niels; Jaeger, Dirk; Yazji, Salim; Scheiflinger, Friedrich; Kerschbaumer, Randolf (2015). "Abstract A153: Imalumab, a first-in-class anti-oxidized macrophage migration inhibitory factor (OxMIF) antibody penetrates tumor tissues and shows antitumor activity in patients". Therapeutic Agents: Biological. pp. A153. doi:10.1158/1535-7163.TARG-15-A153.
- "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.
- "Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.
- "Imalumab - AdisInsight".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.